Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma

Hyunsoo Kim, Nam Chul Kim, Kyu Hee Chae, Gun Kim, Won Seo Park, Yong Koo Park, Youn Wha Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Gallbladder carcinoma (GBCA) is one of the most aggressive malignancies. It is usually diagnosed at an advanced stage, and prognosis remains poor despite advances in imaging techniques and aggressive surgical treatment. Overexpression of multidrug resistance-associated proteins (MRPs) in tumor cells is a major cause of the intrinsic multidrug resistance phenotype. Despite the documented importance of MRP expression in many carcinomas, the prognostic significance of MRP2 expression in primary GBCA is not known. Immunostaining for MRP2 was performed on tissue samples obtained from 143 patients with GBCA. We examined the association between MRP expression and clinicopathological characteristics and outcome of patients with GBCA. GBCA demonstrated MRP2 immunoreactivity in the apicolateral membranes of epithelial cells. MRP2 expression was positive in 53.1% (76/143) of GBCA samples. Positive MRP2 expression was significantly associated with the presence of local recurrence (P=0.038), lymphatic invasion (P=0.038), vascular invasion (P=0.023), and perineural invasion (P=0.006). In addition, the median survival time of patients with MRP2-positive GBCA (15 months) was significantly shorter than that of patients with MRP2-negative GBCA (85 months, P=0.011). We found that the expression of MRP2 in GBCA contributed to aggressive tumor behavior and poor prognosis, suggesting that MRP2 expression can be used as a potential prognostic biomarker of GBCA.

Original languageEnglish
Article number527534
JournalBioMed Research International
Volume2013
DOIs
Publication statusPublished - 2013 Jul 18

Fingerprint

Multidrug Resistance-Associated Proteins
Gallbladder
Carcinoma
Tumors
Biomarkers
Cells
Association reactions
Tissue
Membranes
Imaging techniques
multidrug resistance-associated protein 2
Neoplasms
Multiple Drug Resistance
Blood Vessels
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Kim, Hyunsoo ; Kim, Nam Chul ; Chae, Kyu Hee ; Kim, Gun ; Park, Won Seo ; Park, Yong Koo ; Kim, Youn Wha. / Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma. In: BioMed Research International. 2013 ; Vol. 2013.
@article{de39993d31d1456a8ee850fc9518697b,
title = "Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma",
abstract = "Gallbladder carcinoma (GBCA) is one of the most aggressive malignancies. It is usually diagnosed at an advanced stage, and prognosis remains poor despite advances in imaging techniques and aggressive surgical treatment. Overexpression of multidrug resistance-associated proteins (MRPs) in tumor cells is a major cause of the intrinsic multidrug resistance phenotype. Despite the documented importance of MRP expression in many carcinomas, the prognostic significance of MRP2 expression in primary GBCA is not known. Immunostaining for MRP2 was performed on tissue samples obtained from 143 patients with GBCA. We examined the association between MRP expression and clinicopathological characteristics and outcome of patients with GBCA. GBCA demonstrated MRP2 immunoreactivity in the apicolateral membranes of epithelial cells. MRP2 expression was positive in 53.1{\%} (76/143) of GBCA samples. Positive MRP2 expression was significantly associated with the presence of local recurrence (P=0.038), lymphatic invasion (P=0.038), vascular invasion (P=0.023), and perineural invasion (P=0.006). In addition, the median survival time of patients with MRP2-positive GBCA (15 months) was significantly shorter than that of patients with MRP2-negative GBCA (85 months, P=0.011). We found that the expression of MRP2 in GBCA contributed to aggressive tumor behavior and poor prognosis, suggesting that MRP2 expression can be used as a potential prognostic biomarker of GBCA.",
author = "Hyunsoo Kim and Kim, {Nam Chul} and Chae, {Kyu Hee} and Gun Kim and Park, {Won Seo} and Park, {Yong Koo} and Kim, {Youn Wha}",
year = "2013",
month = "7",
day = "18",
doi = "10.1155/2013/527534",
language = "English",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma. / Kim, Hyunsoo; Kim, Nam Chul; Chae, Kyu Hee; Kim, Gun; Park, Won Seo; Park, Yong Koo; Kim, Youn Wha.

In: BioMed Research International, Vol. 2013, 527534, 18.07.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma

AU - Kim, Hyunsoo

AU - Kim, Nam Chul

AU - Chae, Kyu Hee

AU - Kim, Gun

AU - Park, Won Seo

AU - Park, Yong Koo

AU - Kim, Youn Wha

PY - 2013/7/18

Y1 - 2013/7/18

N2 - Gallbladder carcinoma (GBCA) is one of the most aggressive malignancies. It is usually diagnosed at an advanced stage, and prognosis remains poor despite advances in imaging techniques and aggressive surgical treatment. Overexpression of multidrug resistance-associated proteins (MRPs) in tumor cells is a major cause of the intrinsic multidrug resistance phenotype. Despite the documented importance of MRP expression in many carcinomas, the prognostic significance of MRP2 expression in primary GBCA is not known. Immunostaining for MRP2 was performed on tissue samples obtained from 143 patients with GBCA. We examined the association between MRP expression and clinicopathological characteristics and outcome of patients with GBCA. GBCA demonstrated MRP2 immunoreactivity in the apicolateral membranes of epithelial cells. MRP2 expression was positive in 53.1% (76/143) of GBCA samples. Positive MRP2 expression was significantly associated with the presence of local recurrence (P=0.038), lymphatic invasion (P=0.038), vascular invasion (P=0.023), and perineural invasion (P=0.006). In addition, the median survival time of patients with MRP2-positive GBCA (15 months) was significantly shorter than that of patients with MRP2-negative GBCA (85 months, P=0.011). We found that the expression of MRP2 in GBCA contributed to aggressive tumor behavior and poor prognosis, suggesting that MRP2 expression can be used as a potential prognostic biomarker of GBCA.

AB - Gallbladder carcinoma (GBCA) is one of the most aggressive malignancies. It is usually diagnosed at an advanced stage, and prognosis remains poor despite advances in imaging techniques and aggressive surgical treatment. Overexpression of multidrug resistance-associated proteins (MRPs) in tumor cells is a major cause of the intrinsic multidrug resistance phenotype. Despite the documented importance of MRP expression in many carcinomas, the prognostic significance of MRP2 expression in primary GBCA is not known. Immunostaining for MRP2 was performed on tissue samples obtained from 143 patients with GBCA. We examined the association between MRP expression and clinicopathological characteristics and outcome of patients with GBCA. GBCA demonstrated MRP2 immunoreactivity in the apicolateral membranes of epithelial cells. MRP2 expression was positive in 53.1% (76/143) of GBCA samples. Positive MRP2 expression was significantly associated with the presence of local recurrence (P=0.038), lymphatic invasion (P=0.038), vascular invasion (P=0.023), and perineural invasion (P=0.006). In addition, the median survival time of patients with MRP2-positive GBCA (15 months) was significantly shorter than that of patients with MRP2-negative GBCA (85 months, P=0.011). We found that the expression of MRP2 in GBCA contributed to aggressive tumor behavior and poor prognosis, suggesting that MRP2 expression can be used as a potential prognostic biomarker of GBCA.

UR - http://www.scopus.com/inward/record.url?scp=84880108735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880108735&partnerID=8YFLogxK

U2 - 10.1155/2013/527534

DO - 10.1155/2013/527534

M3 - Article

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 527534

ER -